Annual EBITDA
-$12.29 M
+$6.65 M+35.11%
01 December 2023
Summary:
Plus Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$12.29 million, with the most recent change of +$6.65 million (+35.11%) on 01 December 2023. During the last 3 years, it has fallen by -$5.53 million (-81.63%). PSTV annual EBITDA is now -2210.71% below its all-time high of -$532.00 thousand, reached on 31 December 2019.PSTV EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$2.58 M
-$3.42 M-409.47%
01 September 2024
Summary:
Plus Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$2.58 million, with the most recent change of -$3.42 million (-409.47%) on 01 September 2024. Over the past year, it has increased by +$1.10 million (+29.92%). PSTV quarterly EBITDA is now -145.42% below its all-time high of $5.68 million, reached on 30 June 2015.PSTV Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$8.47 M
+$363.00 K+4.11%
01 September 2024
Summary:
Plus Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$8.47 million, with the most recent change of +$363.00 thousand (+4.11%) on 01 September 2024. Over the past year, it has increased by +$3.82 million (+31.09%). PSTV TTM EBITDA is now -521.44% below its all-time high of $2.01 million, reached on 31 March 2016.PSTV TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTV EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +29.9% | +31.1% |
| 3 y3 years | -81.6% | +24.2% | +26.4% |
| 5 y5 years | -148.2% | -345.1% | -194.4% |
PSTV EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -81.6% | +35.1% | -409.5% | +52.3% | at high | +57.0% |
| 5 y | 5 years | -2210.7% | +35.1% | -282.3% | +52.3% | -2651.5% | +57.0% |
| alltime | all time | -2210.7% | +61.8% | -145.4% | +87.5% | -521.4% | +80.6% |
Plus Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.58 M(-409.5%) | -$8.47 M(-4.1%) |
| June 2024 | - | $834.00 K(-127.4%) | -$8.83 M(-18.6%) |
| Mar 2024 | - | -$3.04 M(-17.4%) | -$10.85 M(-11.7%) |
| Dec 2023 | -$12.29 M(-35.1%) | -$3.68 M(+25.1%) | -$12.29 M(-12.3%) |
| Sept 2023 | - | -$2.94 M(+149.1%) | -$14.02 M(-11.8%) |
| June 2023 | - | -$1.18 M(-73.6%) | -$15.89 M(-19.3%) |
| Mar 2023 | - | -$4.48 M(-17.1%) | -$19.68 M(+3.9%) |
| Dec 2022 | -$18.95 M(+56.9%) | -$5.41 M(+12.1%) | -$18.95 M(+9.2%) |
| Sept 2022 | - | -$4.82 M(-3.0%) | -$17.34 M(+8.9%) |
| June 2022 | - | -$4.97 M(+32.7%) | -$15.92 M(+18.5%) |
| Mar 2022 | - | -$3.75 M(-1.5%) | -$13.43 M(+11.3%) |
| Dec 2021 | -$12.07 M(+78.4%) | -$3.80 M(+11.7%) | -$12.07 M(+4.9%) |
| Sept 2021 | - | -$3.40 M(+37.3%) | -$11.51 M(+21.2%) |
| June 2021 | - | -$2.48 M(+4.0%) | -$9.50 M(+11.6%) |
| Mar 2021 | - | -$2.38 M(-26.4%) | -$8.51 M(+25.7%) |
| Dec 2020 | -$6.77 M(+1172.2%) | -$3.24 M(+133.2%) | -$6.77 M(+220.6%) |
| Sept 2020 | - | -$1.39 M(-6.9%) | -$2.11 M(-735.8%) |
| June 2020 | - | -$1.49 M(+131.8%) | $332.00 K(+0.9%) |
| Mar 2020 | - | -$644.00 K(-145.5%) | $329.00 K(-161.7%) |
| Dec 2019 | -$532.00 K(-89.3%) | $1.42 M(+34.5%) | -$533.00 K(-81.5%) |
| Sept 2019 | - | $1.05 M(-170.4%) | -$2.88 M(-33.4%) |
| June 2019 | - | -$1.50 M(-0.7%) | -$4.32 M(-22.3%) |
| Mar 2019 | - | -$1.51 M(+62.3%) | -$5.56 M(-26.3%) |
| Dec 2018 | -$4.95 M(-73.2%) | -$928.00 K(+136.1%) | -$7.55 M(-24.0%) |
| Sept 2018 | - | -$393.00 K(-85.6%) | -$9.93 M(-25.4%) |
| June 2018 | - | -$2.74 M(-21.6%) | -$13.30 M(-14.0%) |
| Mar 2018 | - | -$3.49 M(+5.5%) | -$15.46 M(-16.3%) |
| Dec 2017 | -$18.49 M(+1.2%) | -$3.31 M(-12.2%) | -$18.49 M(-3.0%) |
| Sept 2017 | - | -$3.77 M(-23.1%) | -$19.07 M(-3.8%) |
| June 2017 | - | -$4.90 M(-24.7%) | -$19.82 M(-2.8%) |
| Mar 2017 | - | -$6.51 M(+67.6%) | -$20.39 M(+11.6%) |
| Dec 2016 | -$18.27 M(+28.0%) | -$3.89 M(-14.0%) | -$18.27 M(+13.4%) |
| Sept 2016 | - | -$4.52 M(-17.5%) | -$16.12 M(+76.1%) |
| June 2016 | - | -$5.48 M(+24.7%) | -$9.15 M(-555.2%) |
| Mar 2016 | - | -$4.39 M(+154.0%) | $2.01 M(-114.1%) |
| Dec 2015 | -$14.27 M(-55.7%) | -$1.73 M(-170.7%) | -$14.27 M(-15.8%) |
| Sept 2015 | - | $2.45 M(-56.9%) | -$16.96 M(-38.0%) |
| June 2015 | - | $5.68 M(-127.5%) | -$27.35 M(-37.3%) |
| Mar 2015 | - | -$20.67 M(+368.0%) | -$43.59 M(+35.3%) |
| Dec 2014 | -$32.22 M(+52.3%) | -$4.42 M(-44.4%) | -$32.22 M(-11.6%) |
| Sept 2014 | - | -$7.94 M(-24.8%) | -$36.44 M(+13.3%) |
| June 2014 | - | -$10.56 M(+13.5%) | -$32.15 M(+35.7%) |
| Mar 2014 | - | -$9.30 M(+7.6%) | -$23.69 M(+12.0%) |
| Dec 2013 | -$21.15 M(-24.4%) | -$8.64 M(+136.4%) | -$21.15 M(+38.1%) |
| Sept 2013 | - | -$3.65 M(+74.1%) | -$15.31 M(-29.7%) |
| June 2013 | - | -$2.10 M(-68.9%) | -$21.79 M(-17.7%) |
| Mar 2013 | - | -$6.76 M(+141.4%) | -$26.48 M(-5.3%) |
| Dec 2012 | -$27.96 M | -$2.80 M(-72.4%) | -$27.96 M(-0.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | -$10.13 M(+49.2%) | -$28.12 M(+5.9%) |
| June 2012 | - | -$6.79 M(-17.6%) | -$26.56 M(-9.0%) |
| Mar 2012 | - | -$8.24 M(+178.4%) | -$29.18 M(+1.3%) |
| Dec 2011 | -$28.81 M(+17.5%) | -$2.96 M(-65.5%) | -$28.81 M(-16.3%) |
| Sept 2011 | - | -$8.57 M(-9.0%) | -$34.42 M(-2.3%) |
| June 2011 | - | -$9.41 M(+19.7%) | -$35.23 M(+15.2%) |
| Mar 2011 | - | -$7.87 M(-8.2%) | -$30.57 M(+24.7%) |
| Dec 2010 | -$24.51 M(+23.4%) | -$8.57 M(-8.5%) | -$24.51 M(-0.4%) |
| Sept 2010 | - | -$9.37 M(+96.8%) | -$24.60 M(+15.8%) |
| June 2010 | - | -$4.76 M(+164.1%) | -$21.25 M(+29.7%) |
| Mar 2010 | - | -$1.80 M(-79.2%) | -$16.39 M(-17.4%) |
| Dec 2009 | -$19.87 M(-29.6%) | -$8.67 M(+43.9%) | -$19.84 M(+16.3%) |
| Sept 2009 | - | -$6.02 M(-6061.4%) | -$17.06 M(-5.8%) |
| June 2009 | - | $101.00 K(-101.9%) | -$18.11 M(-30.9%) |
| Mar 2009 | - | -$5.26 M(-10.6%) | -$26.20 M(-9.3%) |
| Dec 2008 | -$28.23 M(-5.1%) | -$5.88 M(-16.8%) | -$28.88 M(-25.3%) |
| Sept 2008 | - | -$7.07 M(-11.5%) | -$38.65 M(+5.0%) |
| June 2008 | - | -$7.99 M(+0.6%) | -$36.81 M(+6.7%) |
| Mar 2008 | - | -$7.94 M(-49.3%) | -$34.49 M(-1.4%) |
| Dec 2007 | -$29.73 M(+72.3%) | -$15.66 M(+199.6%) | -$34.97 M(+143.9%) |
| Sept 2007 | - | -$5.23 M(-7.8%) | -$14.34 M(-18.1%) |
| June 2007 | - | -$5.67 M(-32.6%) | -$17.50 M(-6.1%) |
| Mar 2007 | - | -$8.41 M(-269.3%) | -$18.64 M(+8.0%) |
| Dec 2006 | -$17.26 M(-33.4%) | $4.97 M(-159.2%) | -$17.26 M(-45.5%) |
| Sept 2006 | - | -$8.39 M(+23.2%) | -$31.67 M(+3.1%) |
| June 2006 | - | -$6.81 M(-3.2%) | -$30.73 M(+6.6%) |
| Mar 2006 | - | -$7.03 M(-25.5%) | -$28.83 M(+11.3%) |
| Dec 2005 | -$25.90 M(+77.0%) | -$9.45 M(+26.9%) | -$25.90 M(+25.9%) |
| Sept 2005 | - | -$7.44 M(+51.3%) | -$20.58 M(+20.9%) |
| June 2005 | - | -$4.92 M(+19.8%) | -$17.03 M(+10.4%) |
| Mar 2005 | - | -$4.10 M(-0.5%) | -$15.43 M(+7.2%) |
| Dec 2004 | -$14.64 M(+93.8%) | -$4.12 M(+6.0%) | -$14.40 M(+30.4%) |
| Sept 2004 | - | -$3.89 M(+17.2%) | -$11.05 M(+20.2%) |
| June 2004 | - | -$3.32 M(+8.1%) | -$9.19 M(+20.7%) |
| Mar 2004 | - | -$3.07 M(+298.7%) | -$7.61 M(+0.8%) |
| Dec 2003 | -$7.55 M(-24.7%) | -$770.00 K(-62.1%) | -$7.55 M(-24.5%) |
| Sept 2003 | - | -$2.03 M(+16.5%) | -$10.00 M(-4.9%) |
| June 2003 | - | -$1.74 M(-42.1%) | -$10.51 M(+2.9%) |
| Mar 2003 | - | -$3.01 M(-6.4%) | -$10.21 M(+1.9%) |
| Dec 2002 | -$10.03 M(-2.2%) | -$3.22 M(+26.6%) | -$10.03 M(+27.7%) |
| Sept 2002 | - | -$2.54 M(+75.4%) | -$7.86 M(-4.1%) |
| June 2002 | - | -$1.45 M(-48.7%) | -$8.20 M(-29.9%) |
| Mar 2002 | - | -$2.83 M(+171.1%) | -$11.69 M(+31.9%) |
| Dec 2001 | -$10.25 M(+11.8%) | -$1.04 M(-63.8%) | -$8.86 M(+13.3%) |
| Sept 2001 | - | -$2.88 M(-41.7%) | -$7.82 M(+58.3%) |
| June 2001 | - | -$4.94 M | -$4.94 M |
| Dec 2000 | -$9.17 M(+104.9%) | - | - |
| Dec 1999 | -$4.47 M(+117.5%) | - | - |
| Dec 1998 | -$2.06 M | - | - |
FAQ
- What is Plus Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Plus Therapeutics?
- What is Plus Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Plus Therapeutics?
- What is Plus Therapeutics quarterly EBITDA year-on-year change?
- What is Plus Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Plus Therapeutics?
- What is Plus Therapeutics TTM EBITDA year-on-year change?
What is Plus Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of PSTV is -$12.29 M
What is the all time high annual EBITDA for Plus Therapeutics?
Plus Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$532.00 K
What is Plus Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of PSTV is -$2.58 M
What is the all time high quarterly EBITDA for Plus Therapeutics?
Plus Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $5.68 M
What is Plus Therapeutics quarterly EBITDA year-on-year change?
Over the past year, PSTV quarterly earnings before interest, taxes, depreciation & amortization has changed by +$1.10 M (+29.92%)
What is Plus Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of PSTV is -$8.47 M
What is the all time high TTM EBITDA for Plus Therapeutics?
Plus Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $2.01 M
What is Plus Therapeutics TTM EBITDA year-on-year change?
Over the past year, PSTV TTM earnings before interest, taxes, depreciation & amortization has changed by +$3.82 M (+31.09%)